A comparative study of mirabegron versus doxazosin in improving ureteral stent-related dysfunction.

ABSTRACT:

Objective

To compare the efficacy of mirabegron and doxazosin in alleviating ureteral stent-related symptoms and sexual dysfunction.

Method

This study included 107 patients who provided informed consent and underwent transurethral ureteral lithotripsy with ureteral stent placement between January 2023 and December 2023. Patients were randomized into two groups receiving either mirabegron (50 mg/day) or doxazosin (4 mg/day). The Ureteral Stent Symptom Questionnaire (USSQ) scores and adverse drug reactions were recorded at baseline (ureteral stent placement), 2 weeks (ureteral stent removal), and 4 weeks (2 weeks after stent removal). The trial was registered with the Chinese Clinical Trial Registry (ChiCTR2500095161).

Results

At 2 weeks, the mirabegron group showed a g

SUBMITTER: Tao B 

PROVIDER: S-EPMC12075346 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature